Locally Advanced or Metastatic Breast Cancer Clinical Trial
Official title:
An Open-Label, Randomized, Multicenter Study Evaluating the Activity of Lasofoxifene Relative to Fulvestrant for the Treatment of Pre- and Postmenopausal Women With Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation
Verified date | April 2024 |
Source | Sermonix Pharmaceuticals Inc. |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This is an open label, randomized, multicenter study evaluating the activity of lasofoxifene relative to fulvestrant for the treatment of pre- and postmenopausal women with locally advanced or metastatic ER+/HER2- breast cancer with an acquired ESR1 mutation and who have disease progression on an aromatase inhibitor (AI) in combination with a cyclin dependent kinase (CDK) 4/6 inhibitor. The primary objective is to evaluate the progression free survival (PFS) of 5 mg lasofoxifene relative to fulvestrant for the treatment of pre- and postmenopausal women with locally advanced or metastatic estrogen receptor positive (ER+)/human epidermal growth factor 2 negative (HER2-) breast cancer with an estrogen receptor 1 (ESR1) mutation. The secondary objectives are to evaluate: 1. Clinical benefit rate (CBR) and Objective Response Rate (ORR) 2. Duration of response 3. Time to response 4. Overall Survival (OS) 5. Pharmacokinetics of lasofoxifene 6. Quality of life (QoL): Quality of Life (QoL): vaginal assessment scale (VAS) and vulvar assessment scale (VuAS) questionnaires 7. Safety of lasofoxifene 8. Response to various ESR1 mutation (Y537S, Y537C, D538G, E380Q, S463P, V534E, P535H, L536H, L536P, L536R, L536Q, or Y537N).
Status | Active, not recruiting |
Enrollment | 100 |
Est. completion date | December 2024 |
Est. primary completion date | December 2024 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: 1. Pre- or postmenopausal. Postmenopausal women are defined as: 1. =60 years of age with no vaginal bleeding over the prior year, or 2. <60 years with "premature menopause" or "premature ovarian failure" manifest itself with secondary amenorrhea for at least 1 year and follicle stimulating hormone (FSH) and estradiol levels in the postmenopausal range according to institutional standards, or 3. surgical menopause with bilateral oophorectomy. Note: premenopausal women who meet all of the other entry criteria must be maintained on ovarian suppression (such as Lupron) during the study and subjects counseled to use appropriate contraception to prevent pregnancy. 2. If possible, a biopsy of metastatic breast cancer tissue will be obtained to provide histological or cytological confirmation of ER+ and HER2- disease as assessed by a local laboratory, according to the American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP) guidelines, using slides, paraffin blocks, or paraffin samples. If a biopsy is not possible, the ER and HER2 status from the tissue obtained at the time of the original diagnosis must confirm that the subject's cancer is ER+ and HER2-. 3. Locally advanced or metastatic breast cancer with radiological or clinical evidence of progression on an AI in combination with a CDK 4/6 inhibitor for advanced breast cancer with demonstrated prior sensitivity to endocrine therapy (recurrence or progression after at least 12 months of treatment in the metastatic setting). 4. Locally advanced or metastatic breast cancer with either measurable (according to RECIST 1.1) or non-measurable lesions. 5. At least one or more of the following point ESR1 mutations as assessed in cell-free circulating tumor DNA (ctDNA) obtained from a blood (plasma) or tissue sample: Y537S, Y537C, D538G, E380Q, S463P, V534E, P535H, L536H, L536P, L536R, L536Q, or Y537N. The ctDNA sample collection must be obtained within 30 days prior to randomization to determine eligibility and baseline. Note: a prior genomic test confirming that the subject has an ESR1 mutation can be used to determine eligibility; however, an ESR1 sample must also be collected within 30 days of randomization. 6. Subjects who have not received cytotoxic chemotherapy or those who have received one cytotoxic chemotherapy regimen in the neo-adjuvant or adjuvant setting prior to entry into the trial and/or no more than one chemotherapy regimen for metastatic breast cancer. Subjects must be free of all chemotherapy acute toxicity excluding alopecia and Grade II peripheral neuropathy before study entry. 7. ECOG performance score of 0 or 1. 8. Adequate organ function as shown by: 1. absolute neutrophil count (ANC) >/=1,500 cells/mm3 2. platelet count =100,000 cells/mm3 3. hemoglobin >/=9.0 g/dl 4. ALT and AST levels =2.5 upper limit of normal (ULN) or =5 in the presence of visceral metastasis 5. total serum bilirubin =1.5 X ULN (= 3 X ULN for subjects known to have Gilbert Syndrome) 6. alkaline phosphatase level = 2.5 X ULN 7. creatinine clearance of 40 ml/min or greater as calculated by the Cockcroft-Gault formula 8. International normalized ratio (INR), activated partial thromboplastin (aPTT), or partial thromboplastin time (PTT) <2.0 X ULN. 9. Able to swallow tablets. 10. Able to understand and voluntarily sign a written informed consent before any screening procedures. Exclusion Criteria: 1. Prior use of everolimus or other mammalian target of rapamycin (mTOR) inhibitor or phosphoinositide 3-kinase inhibitor (PI3K) inhibitors is excluded unless discontinued to reasons other than disease progression. 2. Presence of brain metastasis. 3. Lymphangitic carcinomatosis involving the lung. 4. Impending visceral crisis in need of cytotoxic chemotherapy as assessed by the investigator. 5. Radiotherapy within 30 days prior to randomization except in case of localized radiotherapy for analgesic purposes or for lytic lesions at risk of fracture, which can then be completed within 7 days prior to randomization. Subjects must have recovered from radiotherapy toxicities prior to randomization. 6. History of long QTC syndrome or a QTC of >480 ms. 7. History of a pulmonary embolus (PE) or deep vein thrombosis (DVT) within the last 6 months or any known thrombophilia. Subjects stable on anti-coagulants for maintenance are eligible as long as the DVT and/or PE occurred >6 months prior to enrollment and there is no evidence for active thrombosis. The use of low dose ASA is permitted. 8. Any significant co-morbidity that would impact the study or the subject's safety. 9. History of a positive human immunodeficiency virus (HIV), hepatitis B virus (HBV) or hepatitis C virus (HCV) at Screening. Subjects cured of hepatitis C (no viral load) are eligible. 10. History of malignancy within the past 5 years (excluding breast cancer), except basal cell or squamous cell carcinoma of the skin curatively treated by surgery, or early stage cervical cancer. 11. History of vaginal bleeding over the last year unless it is documented that the bleeding was due to non-uterine causes (e.g. vaginal atrophy). 12. Uncontrolled hypertension defined as sitting systolic pressure >160 mm Hg or diastolic pressure >100 mm Hg at Screening. 13. History of non-compliance to medical regimens. 14. Unwilling or unable to comply with the protocol. 15. Current participation in any clinical research trial involving an investigational drug or device within the last 30 days. |
Country | Name | City | State |
---|---|---|---|
Canada | CIUSSS de Saguenay-Lac-Saint Jean | Chicoutimi | Quebec |
Canada | Jewish General Hospital | Montréal | Quebec |
Canada | McGill University Health Centre | Montréal | Quebec |
Canada | The Ottawa Hospital | Ottawa | Ontario |
Canada | Sunnybrook Health Sciences Center | Toronto | Ontario |
Israel | Soroka University Medical Center | Be'er Sheva | |
Israel | Hadassah Ein Kerem Medical Center | Jerusalem | |
Israel | Rabin Medical Center | Petah tikva | |
Israel | Sheba Medical Center | Ramat Gan | |
United States | Emory University | Atlanta | Georgia |
United States | New Jersey Cancer Care and Blood Disorders (JIT) | Belleville | New Jersey |
United States | Roswell Park Comprehensive Cancer Center | Buffalo | New York |
United States | Tennessee Oncology Chattanooga | Chattanooga | Tennessee |
United States | Robert H. Lurie Comprehensive Cancer Center of Northwestern University | Chicago | Illinois |
United States | University of Chicago | Chicago | Illinois |
United States | TriHealth Cancer Institute | Cincinnati | Ohio |
United States | Ohio Health (JIT) | Columbus | Ohio |
United States | The Ohio State University - Comprehensive Cancer Center | Columbus | Ohio |
United States | Mary Crowley Cancer Research (JIT) | Dallas | Texas |
United States | City of Hope Comprehensive Cancer | Duarte | California |
United States | Duke University Medical Center | Durham | North Carolina |
United States | Summit Medical Group (JIT) | Florham Park | New Jersey |
United States | Compassionate Care Research Group | Fountain Valley | California |
United States | FMH James M Stockman Cancer Institute (JIT) | Frederick | Maryland |
United States | West Cancer Center | Germantown | Tennessee |
United States | Hattiesburg Clinic Hematology/Oncology | Hattiesburg | Mississippi |
United States | Hawaii Cancer Care (JIT) | Honolulu | Hawaii |
United States | Oncology Consultants (JIT) | Houston | Texas |
United States | Mayo Clinic Florida | Jacksonville | Florida |
United States | HCA Midwest Health | Kansas City | Missouri |
United States | Saint Luke's Cancer Institute | Kansas City | Missouri |
United States | Comprehensive Cancer Centers of Nevada (JIT) | Las Vegas | Nevada |
United States | Rocky Mountain Cancer Centers | Longmont | Colorado |
United States | University of Louisville / James Graham Brown Cancer Center | Louisville | Kentucky |
United States | Miami Cancer Institute | Miami | Florida |
United States | Tennessee Oncology/SCRI | Nashville | Tennessee |
United States | Peninsula Cancer Institute | Newport News | Virginia |
United States | Ocala Oncology Center (JIT) | Ocala | Florida |
United States | Illinois Cancer Care (JIT) | Peoria | Illinois |
United States | Mayo Clinic Arizona | Phoenix | Arizona |
United States | UPMC Hillman Cancer Center | Pittsburgh | Pennsylvania |
United States | Mayo Clinic | Rochester | Minnesota |
United States | Washington University School of Medicine | Saint Louis | Missouri |
United States | Utah Cancer Specialists (JIT) | Salt Lake City | Utah |
United States | UCSF Cancer Center | San Francisco | California |
United States | Sanford Cancer Center (JIT) | Sioux Falls | South Dakota |
United States | Beacon Health (JIT) | South Bend | Indiana |
United States | Florida Cancer Specialists | Tallahassee | Florida |
United States | Carle Cancer Center | Urbana | Illinois |
United States | The Bond Clinic Cancer & Research Center. | Winter Haven | Florida |
United States | Yuma Regional Medical Center (JIT) | Yuma | Arizona |
Lead Sponsor | Collaborator |
---|---|
Sermonix Pharmaceuticals Inc. | Linical Accelovance Group |
United States, Canada, Israel,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Progression-Free Survival (PFS) | PFS is defined as the interval from the date of randomization to the earlier date of first documented radiographic progression or death due to any cause | through study completion, an average of 1 year | |
Secondary | Clinical Benefit Rate (CBR) | CBR is defined as the percentage of all subjects with a complete or partial response; or stable disease for >/=24 weeks. | through study completion, an average of 1 year | |
Secondary | Objective Response Rate (ORR) | ORR is defined as the percentage of subjects with either a complete response (CR) or a partial response (PR) as assessed by the RECIST 1.1 criteria. | through study completion, an average of 1 year | |
Secondary | Overall Survival (OS) | OS is defined as time from randomization to death due to any cause. | through study completion, an average of 1 year | |
Secondary | Incidence of Adverse Events (AEs) and Serious AEs | The type, severity (graded by Common Terminology Criteria for Adverse Events [CTCAE version 5.0]), course, duration, seriousness, and relationship to study treatment will be assess at each visit | through study completion, an average of 1 year |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05860465 -
Safety and Efficacy of SPH4336 in Combination With Endocrine Therapy in the Treatment of Locally Advanced or Metastatic Breast Cancer
|
Phase 2/Phase 3 | |
Recruiting |
NCT05054751 -
GB491 Combined With Fulvestrant for HR+ HER2- Locally Advanced or Metastatic Breast Cancer
|
Phase 3 | |
Completed |
NCT03027245 -
Incidence and Resolution of Eribulin-Induced Peripheral Neuropathy
|
||
Not yet recruiting |
NCT05172518 -
Utidelone Plus Capecitabine Versus Taxane Plus Capecitabine in HER2-negative Locally Advanced or Metastatic Breast Cancer
|
Phase 3 | |
Recruiting |
NCT05430399 -
Utidelone Versus Docetaxel in HER2-negative Locally Advanced or Metastatic Breast Cancer
|
Phase 3 | |
Terminated |
NCT00634088 -
Phase I Study of Ixabepilone Plus Lapatinib With or Without Capecitabine in the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer
|
Phase 1 | |
Not yet recruiting |
NCT05403333 -
Weekly Utidelone in HER2-negative Inoperable Locally Advanced or Metastatic Breast Cancer
|
Phase 2 | |
Recruiting |
NCT05296798 -
A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer)
|
Phase 3 | |
Completed |
NCT03437083 -
A Study to Investigate the Efficacy and Safety of Eribulin in Korean Breast Cancer Participants
|
||
Recruiting |
NCT05744687 -
Phase II/III Study of SPH4336 Combined With Letrozole vs Placebo Combined With Letrozole in First-line Treatment of Breast Cancer
|
Phase 2/Phase 3 | |
Active, not recruiting |
NCT06439771 -
A Phase 2 Study to Evaluate the Efficacy, Safety and Pharmacokinetics of YL202 in Patients With BC
|
Phase 2 | |
Withdrawn |
NCT05212701 -
To Assess Efficacy and Safety of Oral Reparixin in Patients With Fatigue and Locally Advanced / Metastatic Breast Cancer
|
Phase 2 |